China has approved its first brain implant designed to help people with paralysis regain some movement in their hands, marking the world's first commercial authorisation for such a device. China's drug regulator, the National Medical Products Administration, said on Friday that it has granted marketing approval to Neuracle Technology (Shanghai) Co. for a brain implant for adult patients who are partially paralyzed due to spinal cord injury.
The regulatory green light, issued in March 2026, represents a critical inflection point in the global race to commercialise neurotechnology. Brain implants have been used as part of clinical trials for decades, but this is the first time such a device has been approved for broad use in patients. By contrast, no BCI devices have been approved for commercial use in the U.S., where companies including Elon Musk's Neuralink remain in extended trial phases.
The device was developed by the Chinese company Neuracle Medical Technology and uses a brain-computer interface (BCI). BCIs connect a person's nervous system to devices capable of interpreting their brain activity, allowing them to act, such as using a computer or moving a prosthetic hand, by the sheer force of their thought. It combines an implanted brain-computer interface (BCI), an implantable EEG electrode kit, and a pneumatic robotic glove that assists with grasping movements.
What distinguishes China's move is the explicit policy machinery driving it. Multiple brain-computer interface startups have received support from the Chinese government, which sees the sector as a growing, strategic industry. That includes pledges to streamline regulatory reviews and reimbursement pathways, as the country seeks to compete globally with companies such as Elon Musk's Neuralink, as well as Synchron, Precision Neuroscience and others. The Chinese government designated brain-computer interface technology as strategically important and set a goal to develop two or three "world class" companies in the sector by 2030.
The clinical evidence is genuine. One participant in the trial, identified only by the surname Dong, joined the study in October 2024. After more than a year of rehabilitation training, he was able to write simple phrases such as "thank you" and his own name without assistance from the brain-computer interface. With the help of the device, Dong was also able to perform tasks he had been unable to do for four years, including lifting a cup, drinking water, and putting the cup back down. However, specialists caution that the technology remains nascent. BCI technology remains in its early stages. "We hope the public understands that current BCI technology cannot instantly resolve symptoms," Mao said. "These technologies cannot be used immediately after implantation and require extensive training and rehabilitation."
The speed of Chinese advancement raises serious questions about the regulatory trade-offs being made. Since February 2025, at least ten clinical trials for invasive brain implants have been launched, and financing activity in the sector is surging: in the first eleven months of 2025 alone, 24 BCI start-ups closed financing rounds, a 30 percent increase from the previous year. This velocity contrasts sharply with the Western model. China's national health insurance means quicker commercialisation once the state approves a device. This compares to the U.S. where even after the FDA approves a device, private insurers, as the main payers, must each individually do so.
Australia's interests in this space deserve closer examination. Chinese dominance in a foundational technology like invasive BCI carries implications for healthcare standards, data sovereignty (neural data represents intimate cognitive information), and technology competition broadly. The Five Eyes intelligence community should monitor not just the technology itself but the governance frameworks being tested. For China, there is currently no legislative plan for neurotechnology; to maintain legal stability and predictability, it can protect users' neurorights through interpretations of the existing legal system. In the near future, it may consider establishing neurorights via special legislation to form a legal system combining general and special protection.
The fundamental tension is real. Patients with severe paralysis have limited options, and they deserve access to promising therapies. But expediting regulation without robust long-term safety data, privacy protections, and informed consent standards invites risks that will outlast the political moment. China's willingness to move fast creates competitive pressure on Western democracies to lower their standards rather than maintain them. That pressure should be resisted, not surrendered to.